Genfit (GNFT)

Genfit S.A. is a late-stage biopharmaceutical company that discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); and GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA). Additionally, Genfit is working on VS-01-ACLF and Nitazoxanide (NTZ), which are in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia. The company is also developing CML-022 and SRT-015, an ASK1 inhibitor that targets the inhibition of cellular apoptosis, inflammation, and fibrosis. Genfit has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test, and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.